Adamas Pharmaceuticals INC (ADMS) Shares Declined While Broadfin Capital LLC Has Upped Holding by $7.05 Million

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Logo

Broadfin Capital Llc increased its stake in Adamas Pharmaceuticals Inc (ADMS) by 24.83% based on its latest 2018Q2 regulatory filing with the SEC. Broadfin Capital Llc bought 281,918 shares as the company’s stock declined 17.64% while stock markets rallied. The hedge fund held 1.42 million shares of the health care company at the end of 2018Q2, valued at $36.60 million, up from 1.14M at the end of the previous reported quarter. Broadfin Capital Llc who had been investing in Adamas Pharmaceuticals Inc for a number of months, seems to be bullish on the $272.81 million market cap company. The stock decreased 0.30% or $0.03 during the last trading session, reaching $9.98. About 412,860 shares traded. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has risen 9.07% since December 8, 2017 and is uptrending. It has underperformed by 6.55% the S&P500.

Broadfin Capital Llc, which manages about $1.26 billion and $635.22M US Long portfolio, decreased its stake in Integra Lifesciences Hldgs C (NASDAQ:IART) by 135,000 shares to 163,424 shares, valued at $10.53 million in 2018Q2, according to the filing. It also reduced its holding in Iovance Biotherapeutics Inc (Call) by 885,487 shares in the quarter, leaving it with 27,500 shares, and cut its stake in Heron Therapeutics Inc (Call) (NASDAQ:HRTX).

More notable recent Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) news were published by: Seekingalpha.com which released: “Adamas Pharma operating chief bids adieu – Seeking Alpha” on September 14, 2018, also Nasdaq.com with their article: “Notable Friday Option Activity: ADMS, POST, AAOI – Nasdaq” published on August 03, 2018, Seekingalpha.com published: “Premarket analyst action – healthcare – Seeking Alpha” on October 05, 2018. More interesting news about Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) were released by: Globenewswire.com and their article: “Adamas Reports First Quarter 2018 Financial Results Nasdaq:ADMS – GlobeNewswire” published on May 03, 2018 as well as Nasdaq.com‘s news article titled: “Why Adamas Pharmaceuticals Fell Today – Nasdaq” with publication date: February 20, 2018.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Coverage

Among 4 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Adamas Pharmaceuticals had 5 analyst reports since June 22, 2018 according to SRatingsIntel. The stock of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) earned “Buy” rating by Mizuho on Friday, June 22. The stock of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has “Neutral” rating given on Friday, October 5 by Bank of America. The rating was downgraded by Mizuho on Monday, November 5 to “Neutral”.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.